Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice
We are currently witnessing a dramatic shift in our approach to the treatment of B-cell non-Hodgkin lymphoma (B-NHL). In the evolving clinical landscape, novel treatments for this clinically heterogeneous disease span a wide range of interventions, encompassing targeted agents, cell therapy approach...
Main Authors: | Rita Tavarozzi, Giulia Zacchi, Daniela Pietrasanta, Gioacchino Catania, Alessia Castellino, Federico Monaco, Carolina Gandolfo, Paolo Rivela, Antonella Sofia, Noemi Schiena, Claudia Bertassello, Giulia Limberti, Francesco Zallio, Manuela Zanni, Marco Ladetto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/22/5397 |
Similar Items
-
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
by: Theodoros P. Vassilakopoulos, et al.
Published: (2023-08-01) -
Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma
by: Kuang Z, et al.
Published: (2021-12-01) -
Mycosis fungoides, lymphomatoid papulosis and Hodgkin's lymphoma in the same patient: Apropos of a possible monoclonal origin
by: Montserrat Molgó, et al.
Published: (2020-01-01) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01) -
Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
by: Navalkele BD, et al.
Published: (2018-01-01)